comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 05:03:51 - browse：73

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： What does generative AI mean for health care? We asked experts

focus

WSS

Duchenne breakthrough therapy leaves behind pioneering families

Supreme Court strikes down use of affirmative action

In Memoriam: Notable people who died in 2023

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

leisure time

comprehensive

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Virginia high school admissions case could be legal follow

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Continuity nursing helped my family in our darkest PICU moments

At least 13 dead in Texas as scorching temps continue

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

In Memoriam: Notable people who died in 2023

Affirmative action in medical school literally saved lives

hotspot

Bright Health sells Medicare Advantage business to Molina

HIV vaccine remains elusive. Immunologists keep trying new ideas

HIV vaccine remains elusive. Immunologists keep trying new ideas

Second House panel advances two

Venture capitalist Bob Kocher on the state of digital health

BioMarin wins approval for gene therapy to treat hemophilia A

focus

leisure time

focus

hotspot